In early 2019, the 6th World Symposium on Pulmonary Hypertension (WSPH) released an
updated document highlighting the advances in the last five years. During the quinquennial …

Pulmonary hypertension (PH) is a rare heterogenous disease characterized by elevated
blood pressure in the lungs. Patients with PH require careful evaluation and management at …

The past 20 years have seen major advances in the diagnosis and management of
pulmonary hypertension, a disease associated with significant morbidity and mortality. The …

Pulmonary arterial hypertension (PAH) is a severe disease characterised by a progressive
increase of pulmonary pressure and resistance leading to right heart failure. PAH is …

Pulmonary arterial hypertension (PAH) is a rare disease, but one that continues to cause
significant morbidity and mortality despite much recent therapeutic progress. PAH is one …

Pulmonary hypertension (PH) comprises a heterogeneous group of disorders characterised
by increased pulmonary vascular resistance that results in progressive right ventricular …

Pulmonary hypertension (PH) is a chronic, complex and challenging disease. Advances in
treatment are for the subset of patients with pulmonary arterial hypertension. Selected …

The term pulmonary arterial hypertension (PAH) identifies a heterogeneous group of
diseases characterized by a progressive increase in pulmonary arterial resistance (PVR) …

But the diverse molecular pathways that lead to the same endresult are lost by WHO
classifications, which are driven by a diagnosis of exclusion, using common tests to prove …

Pulmonary arterial hypertension (PAH) is a progressive disease. Although great progress
has been made in its diagnosis and treatment in recent years, its mortality rate is still very …